BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 19906524)

  • 1. Redefining the role of interferon in the treatment of malignant diseases.
    Bracarda S; Eggermont AM; Samuelsson J
    Eur J Cancer; 2010 Jan; 46(2):284-97. PubMed ID: 19906524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review.
    Wadler S; Schwartz EL
    Cancer Res; 1990 Jun; 50(12):3473-86. PubMed ID: 1692761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of interferons in the treatment of solid tumors.
    Wadler S
    Cancer; 1992 Aug; 70(4 Suppl):949-58. PubMed ID: 1379117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy and chemoimmunotherapy in disseminated malignant melanoma.
    Garbe C
    Melanoma Res; 1993 Aug; 3(4):291-9. PubMed ID: 7693093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenges facing antiangiogenic therapy for cancer: impact of the tumor extracellular environment.
    Gagne P; Akalu A; Brooks PC
    Expert Rev Anticancer Ther; 2004 Feb; 4(1):129-40. PubMed ID: 14748663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of metastatic renal cell carcinoma.
    Reeves DJ; Liu CY
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):11-25. PubMed ID: 19343348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Interferons in the therapy of solid tumors].
    Tomao S; Mozzicafreddo A; Raffaele M; Romiti A; Papò MA; Campisi C
    Clin Ter; 1995; 146(8-9):491-502. PubMed ID: 8536432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A third-generation bisphosphonate, minodronic acid (YM529), augments the interferon alpha/beta-mediated inhibition of renal cell cancer cell growth both in vitro and in vivo.
    Yuasa T; Nogawa M; Kimura S; Yokota A; Sato K; Segawa H; Kuroda J; Maekawa T
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):853-9. PubMed ID: 15701876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting cancer with phosphodiesterase inhibitors.
    Savai R; Pullamsetti SS; Banat GA; Weissmann N; Ghofrani HA; Grimminger F; Schermuly RT
    Expert Opin Investig Drugs; 2010 Jan; 19(1):117-31. PubMed ID: 20001559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons.
    Pfeffer LM; Dinarello CA; Herberman RB; Williams BR; Borden EC; Bordens R; Walter MR; Nagabhushan TL; Trotta PP; Pestka S
    Cancer Res; 1998 Jun; 58(12):2489-99. PubMed ID: 9635566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon in metastatic renal cell carcinoma.
    Fosså SD
    Semin Oncol; 2000 Apr; 27(2):187-93. PubMed ID: 10768597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon-alpha inhibits in vitro osteoclast differentiation and renal cell carcinoma-induced angiogenesis.
    Avnet S; Cenni E; Perut F; Granchi D; Brandi ML; Giunti A; Baldini N
    Int J Oncol; 2007 Feb; 30(2):469-76. PubMed ID: 17203230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of interferons in the treatment of malignant neoplasms.
    Murren JR; Buzaid AC
    Yale J Biol Med; 1989; 62(3):271-90. PubMed ID: 2479178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The interferons.
    Itri LM
    Cancer; 1992 Aug; 70(4 Suppl):940-5. PubMed ID: 1379116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted therapy of renal cell cancer.
    Wysocki PJ; Zolnierek J; Szczylik C; Mackiewicz A
    Curr Opin Investig Drugs; 2008 Jun; 9(6):570-5. PubMed ID: 18516756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EORTC-GU group expert opinion on metastatic renal cell cancer.
    de Reijke TM; Bellmunt J; van Poppel H; Marreaud S; Aapro M
    Eur J Cancer; 2009 Mar; 45(5):765-73. PubMed ID: 19157861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Current status of interferon therapy].
    Dittrich C
    Wien Med Wochenschr; 1986 Apr; 136(7-8):163-72. PubMed ID: 2425497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IFN-alpha and novel strategies of combination therapy for cancer.
    Bracci L; Proietti E; Belardelli F
    Ann N Y Acad Sci; 2007 Sep; 1112():256-68. PubMed ID: 17567945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.